Advancing Innovative Cellular Therapies

What We Do

Avaí Bio focuses on identifying genetically modified cell lines globally to tackle challenging diseases or medical conditions and then developing therapies that supply what a patient’s body can no longer provide effectively. The success of these cell lines depends on their safe delivery into the body and the subsequent protection from the patient’s immune system. To achieve this, Avaí Bio has teamed up with a cell encapsulation company utilizing cutting-edge encapsulation technology to shield these cells.

About Us

At Avaí Bio, we are partnering with leading-edge biotech firms, universities, scientists, and clinicians to uncover innovative solutions for diverse healthcare challenges, driving the development of advanced therapies that improve patient outcomes and quality of life. Our mission is to transform healthcare through cutting-edge cellular technology and protective live-cell encapsulation, reshaping how patients see their available treatment options.

Our Development Pipeline

Avaí Bio currently has two development programs in its cellular therapies pipeline, a diabetes development program and a α-Klotho protein development program. Avaí has secured Joint Venture and Licensing Agreements to develop both cell lines.

α-Klotho Development Program

Developing a genetically modified cell line that overexpresses the production of the α-Klotho protein for age-related treatments and anti-aging therapies.

Diabetes Development Program

Developing a cell line that is genetically modified to produce, store and secrete insulin in type 1 and insulin-dependent type 2 diabetics.